{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:44:50Z","timestamp":1792118690039,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,17]]},"DOI":"10.7759\/cureus.80725","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T19:09:36Z","timestamp":1742238576000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Cannabinoids for Autism Spectrum Disorder: An Updated Systematic Review"],"prefix":"10.7759","author":[{"given":"Danilo A","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Cheidde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus Daniel R","family":"Megiolaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Elisa F","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabet Taylor P","family":"Weba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson M","family":"Pereira da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cheidde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Paulo","family":"Ladeira J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillan C","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Triaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus Augusto N","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Maria P","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.23661","article-title":"Autism spectrum disorder: a review","volume":"329","author":"Hirota T","year":"2023","unstructured":"Hirota T, King BH. Autism spectrum disorder: a review. JAMA. 2023, 329:157-68. 10.1001\/jama.2022.23661","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2017.19.4\/rfindling","article-title":"Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents","volume":"19","author":"Stepanova E","year":"2017","unstructured":"Stepanova E, Dowling S, Phelps M, Findling RL. Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues Clin Neurosci. 2017, 19:395-402. 10.31887\/DCNS.2017.19.4\/rfindling","journal-title":"Dialogues Clin Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial","volume":"12","author":"Aran A","year":"2021","unstructured":"Aran A, Harel M, Cassuto H, et al.. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism. 2021, 12:6. 10.1186\/s13229-021-00420-2","journal-title":"Mol Autism"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-021-00801-x","article-title":"Cannabinoid receptors distribution in mouse cortical plasma membrane compartments","volume":"14","author":"Miranzadeh Mahabadi H","year":"2021","unstructured":"Miranzadeh Mahabadi H, Bhatti H, Laprairie RB, Taghibiglou C. Cannabinoid receptors distribution in mouse cortical plasma membrane compartments. Mol Brain. 2021, 14:89. 10.1186\/s13041-021-00801-x","journal-title":"Mol Brain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03202-8","article-title":"CB2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions","volume":"21","author":"Grabon W","year":"2024","unstructured":"Grabon W, Ruiz A, Gasmi N, et al.. CB2 expression in mouse brain: from mapping to regulation in microglia under inflammatory conditions. J Neuroinflammation. 2024, 21:206. 10.1186\/s12974-024-03202-8","journal-title":"J Neuroinflammation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111400652","article-title":"CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity","volume":"26","author":"Onaivi ES","year":"2012","unstructured":"Onaivi ES, Ishiguro H, Gu S, Liu QR. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol. 2012, 26:92-103. 10.1177\/0269881111400652","journal-title":"J Psychopharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030586","article-title":"The endocannabinoid system and PPARs: focus on their signalling crosstalk, action and transcriptional regulation","volume":"10","author":"Iannotti FA","year":"2021","unstructured":"Iannotti FA, Vitale RM. The endocannabinoid system and PPARs: focus on their signalling crosstalk, action and transcriptional regulation. Cells. 2021, 10:586. 10.3390\/cells10030586","journal-title":"Cells"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01612-3","article-title":"Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder","volume":"11","author":"Poleg S","year":"2021","unstructured":"Poleg S, Kourieh E, Ruban A, Shapira G, Shomron N, Barak B, Offen D. Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder. Transl Psychiatry. 2021, 11:524.","journal-title":"Transl Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031001","article-title":"Relevance of peroxisome proliferator activated receptors in multitarget paradigm associated with the endocannabinoid system","volume":"22","author":"Fernandez A","year":"2021","unstructured":"Fernandez A, Zarzo-Arias S, Jagerovic N, et al.. Relevance of peroxisome proliferator activated receptors in multitarget paradigm associated with the endocannabinoid system. Int J Mol Sci. 2021, 22:1001. 10.3390\/ijms22031001","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212453","article-title":"The evolving role of cannabidiol-rich cannabis in people with autism spectrum disorder: a systematic review","volume":"25","author":"Jawed B","year":"2024","unstructured":"Jawed B, Esposito JE, Pulcini R, et al.. The evolving role of cannabidiol-rich cannabis in people with autism spectrum disorder: a systematic review. Int J Mol Sci. 2024, 25:12453. 10.3390\/ijms252212453","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/cch.12909","article-title":"Medicinal cannabis in children and adolescents with autism spectrum disorder: a scoping review","volume":"48","author":"Fletcher S","year":"2022","unstructured":"Fletcher S, Pawliuk C, Ip A, Huh L, Rassekh SR, Oberlander TF, Siden H. Medicinal cannabis in children and adolescents with autism spectrum disorder: a scoping review. Child Care Health Dev. 2022, 48:33-44. 10.1111\/cch.12909","journal-title":"Child Care Health Dev"},{"key":"ref12","unstructured":"Cochrane. (2018). Accessed. January 28, 2025: https:\/\/training.cochrane.org\/handbook."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.47626\/2237-6089-2021-0396","article-title":"Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial","volume":"46","author":"Junior EAS","year":"2024","unstructured":"Junior EAS, Medeiros WM, Santos JP, et al.. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. Trends Psychiatry Psychother. 2024, 46:e20210396. 10.47626\/2237-6089-2021-0396","journal-title":"Trends Psychiatry Psychother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071685","article-title":"A placebo-controlled trial of cannabinoid treatment for disruptive behavior in children and adolescents with autism spectrum disorder: effects on sleep parameters as measured by the CSHQ","volume":"10","author":"Schnapp A","year":"2022","unstructured":"Schnapp A, Harel M, Cayam-Rand D, Cassuto H, Polyansky L, Aran A. A placebo-controlled trial of cannabinoid treatment for disruptive behavior in children and adolescents with autism spectrum disorder: effects on sleep parameters as measured by the CSHQ. Biomedicines. 2022, 10:1685. 10.3390\/biomedicines10071685","journal-title":"Biomedicines"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02104-8","article-title":"Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study","volume":"12","author":"Hacohen M","year":"2022","unstructured":"Hacohen M, Stolar OE, Berkovitch M, et al.. Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study. Transl Psychiatry. 2022, 12:375. 10.1038\/s41398-022-02104-8","journal-title":"Transl Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37570-y","article-title":"Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy","volume":"9","author":"Bar-Lev Schleider L","year":"2019","unstructured":"Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019, 9:200. 10.1038\/s41598-018-37570-y","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities","volume":"9","author":"Barchel D","year":"2019","unstructured":"Barchel D, Stolar O, De-Haan T, et al.. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol. 2019, 9:1521. 10.3389\/fphar.2018.01521","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study","volume":"49","author":"Aran A","year":"2019","unstructured":"Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems-a retrospective feasibility study. J Autism Dev Disord. 2019, 49:1284-8. 10.1007\/s10803-018-3808-2","journal-title":"J Autism Dev Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-021-00108-7","article-title":"CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature","volume":"3","author":"Bilge S","year":"2021","unstructured":"Bilge S, Ekici B. CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature. J Cannabis Res. 2021, 3:53. 10.1186\/s42238-021-00108-7","journal-title":"J Cannabis Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2020.100833","article-title":"Autism spectrum disorder and medical cannabis: review and clinical experience","volume":"35","author":"Mostafavi M","year":"2020","unstructured":"Mostafavi M, Gaitanis J. Autism spectrum disorder and medical cannabis: review and clinical experience. Semin Pediatr Neurol. 2020, 35:100833. 10.1016\/j.spen.2020.100833","journal-title":"Semin Pediatr Neurol"},{"key":"ref22","article-title":"Clinical and family implications of cannabidiol (CBD)-dominant full-spectrum phytocannabinoid extract in children and adolescents with moderate to severe non-syndromic autism spectrum disorder (ASD): an observational study on neurobehavioral management","volume":"17","author":"Mazza JAS","year":"2024","unstructured":"Mazza JAS, Ferreira L, Martins-Viera S, et al.. Clinical and family implications of cannabidiol (CBD)-dominant full-spectrum phytocannabinoid extract in children and adolescents with moderate to severe non-syndromic autism spectrum disorder (ASD): an observational study on neurobehavioral management. Pharmaceuticals. 2024, 17:686.","journal-title":"Pharmaceuticals"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10090572","article-title":"Cannabinoids for people with ASD: a systematic review of published and ongoing studies","volume":"10","author":"Fusar-Poli L","year":"2020","unstructured":"Fusar-Poli L, Cavone V, Tinacci S, et al.. Cannabinoids for people with ASD: a systematic review of published and ongoing studies. Brain Sci. 2020, 10:90572. 10.3390\/brainsci10090572","journal-title":"Brain Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28442","article-title":"Cannabidiol in treatment of autism spectrum disorder: a case study","volume":"14","author":"Ma L","year":"2022","unstructured":"Ma L, Platnick S, Platnick H. Cannabidiol in treatment of autism spectrum disorder: a case study. Cureus. 2022, 14:e28442. 10.7759\/cureus.28442","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01145","article-title":"Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use","volume":"10","author":"Fleury-Teixeira P","year":"2019","unstructured":"Fleury-Teixeira P, Caixeta FV, Ramires da Silva LC, Brasil-Neto JP, Malcher-Lopes R. Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use. Front Neurol. 2019, 10:1145. 10.3389\/fneur.2019.01145","journal-title":"Front Neurol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.635763","article-title":"Is cannabidiol during neurodevelopment a promising therapy for schizophrenia and autism spectrum disorders?","volume":"11","author":"Loss CM","year":"2021","unstructured":"Loss CM, Teodoro L, Rodrigues GD, et al.. Is cannabidiol during neurodevelopment a promising therapy for schizophrenia and autism spectrum disorders?. Front Pharmacol. 2021, 11:635763. 10.3389\/fphar.2020.635763","journal-title":"Front Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2024.05.002","article-title":"Therapeutic potential of CBD in autism spectrum disorder","volume":"177","author":"Pedrazzi JFC","year":"2024","unstructured":"Pedrazzi JFC, Hassib L, Ferreira FR, Hallak JC, Del-Bel E, Crippa JA. Therapeutic potential of CBD in autism spectrum disorder. Int Rev Neurobiol. 2024, 177:149-203. 10.1016\/bs.irn.2024.05.002","journal-title":"Int Rev Neurobiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1243597","article-title":"Comparison of various doses of oral cannabidiol for treating refractory epilepsy indications: a network meta-analysis","volume":"15","author":"Wang X","year":"2024","unstructured":"Wang X, Zhu H, Liu T, Guo Z, Zhao C, He Z, Zheng W. Comparison of various doses of oral cannabidiol for treating refractory epilepsy indications: a network meta-analysis. Front Neurol. 2024, 15:1243597. 10.3389\/fneur.2024.1243597","journal-title":"Front Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116049","article-title":"Therapeutic potential of cannabidiol (CBD) in anxiety disorders: a systematic review and meta-analysis","volume":"339","author":"Han K","year":"2024","unstructured":"Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol (CBD) in anxiety disorders: a systematic review and meta-analysis. Psychiatry Res. 2024, 339:116049. 10.1016\/j.psychres.2024.116049","journal-title":"Psychiatry Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-024-01847-w","article-title":"Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC)","volume":"49","author":"Lo LA","year":"2024","unstructured":"Lo LA, Christiansen AL, Strickland JC, Pistawka CA, Eadie L, Vandrey R, MacCallum CA. Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC). Neuropsychopharmacology. 2024, 49:1425-36. 10.1038\/s41386-024-01847-w","journal-title":"Neuropsychopharmacology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/347254-efficacy-and-safety-of-cannabinoids-for-autism-spectrum-disorder-an-updated-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T19:09:39Z","timestamp":1742238579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/347254-efficacy-and-safety-of-cannabinoids-for-autism-spectrum-disorder-an-updated-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.80725","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}